Study: 17% of HCV patients have contraindication to therapy

01/28/2013 | Medscape (free registration)

A study found 17.3% of patients with chronic hepatitis C had a contraindication to pegylated interferon and ribavirin therapy, but most were treatable or transient. Bipolar disorders, anemia and pregnancy were the most common contraindications, according to researchers from State University of New York in Buffalo. Those with contraindications tended to be white, younger, female, unmarried and covered by public insurance.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ